Please use this identifier to cite or link to this item:
Title: Patents Protecting Biologics or Small Molecule Drugs are Litigated, not Others Awarded to Drug Discovery Companies
Authors: Mehrotra, Bagish
Saberwal, Gayatri
Keywords: Patents;Patent litigation;Intellectual property;USPTO;Litigation database;Patent maintenance
Issue Date: May-2016
Publisher: NISCAIR-CSIR, India
Abstract: Assuming that litigated patents are valuable, the incidence of litigation for patents protecting biologics (146 patents), small molecules (1822) or issued to drug-discovery companies per se (1929) was examined. This was done by accessing the litigation database of the company MaxVal Group Inc. (20%) of those protecting biologics, 40% protecting small molecules and 1% of those issued to the companies were litigated (although only 0.3% of those issued to companies that do not protect biologics or small molecules). The average time between the grant of a patent and its first litigation was 15.7, 7.8 and 2.7 (2.0) years respectively. Thus, the relevant patents of this study were litigated much later than the average litigated patent. Each litigated patent was litigated 1.7, 5.6 and 2.4 (1.0) times respectively. In each category, most litigants were companies, with very few litigations involving academic institutions or the USPTO, and no non-profit organizations. These results should be of interest to drug-discovery companies, to those who fund or acquire such companies and to non-profit drug-discovery centres.
Page(s): 149-156
ISSN: 0975-1076 (Online); 0971-7544 (Print)
Appears in Collections:JIPR Vol.21(3) [May 2016]

Files in This Item:
File Description SizeFormat 
JIPR 21(3) 149-156.pdf50.78 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.